GTCR will acquire Surmodics for approximately $627 million and then take the company private, according to a news release.
Surmodics (Nasdaq: SRDX), founded in 1979 and based in Eden Prairie, Minnesota, is a provider of medical device and in vitro diagnostic technologies.
GTCR, based in Chicago, pursues a wide range of investments in several industries, including healthcare. Founded in 1980, the firm prefers to make more substantial investments from a dollars perspective.
The acquisition is expected to close in the second half of 2024.
